title: Gamma-interferon-induced monocyte major histocompatibility complex class II antigen expression individuals with acquired immune deficiency syndrome.
abstract: Twelve patients with the acquired immune deficiency syndrome (AIDS) and Kaposi's sarcoma were treated with recombinant human gamma-interferon (rIFN-gamma). A rapid, substantial increase in the fraction of HLA-DQ-positive monocytes was noted after treatment with rIFN-gamma. The rIFN-gamma-induced increase in monocyte HLA-DQ was seen throughout the course of treatment, with the percentage of HLA-DQ-positive monocytes dropping slightly following each week's treatment with rIFN-gamma and then rapidly increasing following the next course of treatment. Although the percentage of HLA-DR-positive monocytes was unchanged (HLA-DR was expressed on greater than 80% of monocytes prior to treatment), the density of HLA-DR on monocytes also increased following rIFN-gamma treatment. Following rIFN-gamma treatment, no changes were seen in CD3, CD4, CD8 T cell numbers, in T cell subset ratio (CD4/CD8), in Leu 7 or CD16 (Leu 11) cell number, in spontaneous Ig secretion, in PHA-induced in vitro proliferation, or in NK activity. These results indicate that exposure to rIFN-gamma in vivo led to the increased expression of class II antigens on monocytes in patients with AIDS.
authors.affiliation: Department of Microbiology and Immunology, UCLA School of Medicine 90024.
authors.forename: O
authors.initials: O
authors.lastname: Martínez-Maza
authors.forename: R T
authors.initials: RT
authors.lastname: Mitsuyasu
authors.forename: S A
authors.initials: SA
authors.lastname: Miles
authors.forename: J V
authors.initials: JV
authors.lastname: Giorgi
authors.forename: D F
authors.initials: DF
authors.lastname: Heitjan
authors.forename: S A
authors.initials: SA
authors.lastname: Sherwin
authors.forename: J L
authors.initials: JL
authors.lastname: Fahey
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000628:therapy; D004305:Dose-Response Relationship, Drug; D006681:HLA-D Antigens / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate; D007136:Immunoglobulins / Q000378:metabolism; D007371:Interferon-gamma / Q000494:pharmacology* / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology; D007958:Leukocyte Count / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000276:immunology; D009000:Monocytes / Q000276:immunology*; D011994:Recombinant Proteins; D012514:Sarcoma, Kaposi / Q000276:immunology* / Q000628:therapy
chemical_list: D006681:HLA-D Antigens; D007136:Immunoglobulins; D011994:Recombinant Proteins; D007371:Interferon-gamma